Histogen IncNASDAQ:HSTO
- LAST PRICE0.8319
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8110/ 4
- Ask / Lots0.9900/ 13
- Open / Previous Close0.0000 / 0.8319
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HSTO |
|---|---|---|
| 11:45 ET | 540 | 0.835 |
| 12:02 ET | 3500 | 0.835 |
| 12:03 ET | 300 | 0.835 |
| 12:18 ET | 100 | 0.835 |
| 12:21 ET | 230 | 0.8115 |
| 12:27 ET | 2739 | 0.86 |
| 12:39 ET | 100 | 0.85 |
| 12:41 ET | 100 | 0.854 |
| 01:35 ET | 902 | 0.8481 |
| 02:45 ET | 200 | 0.852 |
| 02:47 ET | 600 | 0.8325 |
| 03:09 ET | 803 | 0.8201 |
| 03:50 ET | 100 | 0.844949 |
| 03:56 ET | 536 | 0.8319 |
May 11, 2023
BRIEF-Histogen Reports First Quarter 2023 Results And Provides Business Update, from 4:12PM ET on Thursday May 11, 2023 by Thomson Reuters
4:12PM ET on Thursday May 11, 2023 by Thomson ReutersHistogen Reports First Quarter 2023 Results and Provides Business Update, from 4:05PM ET on Thursday May 11, 2023 by GlobeNewswire
4:05PM ET on Thursday May 11, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Histogen Inc | 3.6M | -0.2x | --- |
Acura Pharmaceuticals Inc | 3.3M | -1.8x | --- |
Stemtech Corp | 3.7M | -0.3x | --- |
OpGen Inc | 4.3M | 0.0x | --- |
Ensysce Biosciences Inc | 3.9M | 0.0x | --- |
Antigenics Inc | 340.0 | 0.0x | --- |
Company Information
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Contact Information
- Headquarters
- 10655 SORRENTO VALLEY ROAD, SUITE 200SAN DIEGO, CA, United States 92121
- Phone
- 858-526-3100
- Fax
- 302-636-5454
Executives
- Non-Executive Chairman of the Board
- Daniel Kisner
- President, Chief Executive Officer
- Steven Mento
- Chief Financial Officer, Executive Vice President, Corporate Secretary
- Susan Knudson
- Executive Vice President, Chief Scientific Officer
- Alfred Spada
- Senior Vice President - Research
- Martin Latterich
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6M |
|---|---|
Revenue (TTM) | $19.0K |
Shares Outstanding | 4.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.33 |
EPS | $-4.07 |
Book Value | $3.37 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 187.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -70,700.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
